undamentalytics Newsletter

Czirr James C: insider trades

Officer, Director, 10% owner at Galectin Therapeutics Inc. 1 open-market purchase and 7 sales not made under a pre-set plan, reported from May 18, 2012 to December 18, 2025.

Would copying Czirr James C’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved −61.9% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Czirr James C: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 3 +6.1% +15.1% 33% 3 — — Not enough years
Sales, 12 months after the report 3 −61.9% −74.2% 100% 3 — — Not enough years
Sales, 12 months after the trade 2 −83.3% −83.3% 100% 2 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Galectin Therapeutics Inc GALT Executive Chairman17May 18, 2012December 18, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
December 18, 2025December 16, 2025 GALT Sale $204,335 not yetnot yetnot yet
April 25, 2024April 22, 2024 GALT Sale $76,500 not yetnot yetnot yet
June 5, 2018June 1, 2018 GALT Sale $256,081 +15.1%−26.9%not yet
January 29, 2018January 25, 2018 GALT Sale $1,328,290 not yetnot yetnot yet
April 21, 2016April 19, 2016 GALT Sale $74,097 not yetnot yetnot yet
January 14, 2014January 10, 2014 GALT Sale $1,484,000 −22.3%−84.8%−88.0%
October 9, 2013October 7, 2013 GALT Sale $1,327,320 +25.5%−74.2%−78.5%
May 18, 2012May 17, 2012 GALT Purchase $22,500 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Czirr James C traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.